TRANSGENE Provides An Update On Its Development Strategy And On Its First Half-Year 2016 Financials
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris:TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today announced its financial results for the six-month period ended June 30, 2016 and published an update on its business and on the development of its portfolio of therapeutic vaccines and oncolytic viruses.
Since the beginning of the year, Transgene has focused its efforts on implementing its strategy aimed at combining Transgene’s immunotherapies with other immunotherapy treatment approaches, in particular immune checkpoint inhibitors (ICIs). The power of these combinations was the subject of great interest at the recent annual American Society of Clinical Oncology (ASCO) meeting that was held in Chicago in June.
Since the beginning of the year, Transgene has focused its efforts on implementing its strategy aimed at combining Transgene’s immunotherapies with other immunotherapy treatment approaches, in particular immune checkpoint inhibitors (ICIs). The power of these combinations was the subject of great interest at the recent annual American Society of Clinical Oncology (ASCO) meeting that was held in Chicago in June.